The Difference a Decade Makes

Jennifer Zelmer
2015 Healthcare Policy | Politiques de Santé  
T he decade since Healthcare Policy/Politiques de Santé was founded has seen many waves of change, both within the health sector and beyond. Yet throughout these changes -or perhaps because of them -the need for a credible, curated home for policy-relevant research and evidence-informed discussion and debate has remained constant. Our ability to deliver on this mandate has been helped by our relationship with the Canadian Association of Health Services and Policy Research (CAHSPR), as well as
more » ... olving mechanisms for sharing the journal' s content. These include an on-going partnership with EvidenceNetwork.ca to make key findings available to the media and full indexing in Medline/PubMed to expand the accessibility and global reach of the content that we publish. Over the last decade, the journal' s most-read articles have reflected a wide range of topical issues in healthcare policy. Examples include publications on benchmarking for continuous quality improvement, logic models for primary healthcare, developing health policy and systems research in Nigeria and global approaches to the evaluation of health services use. Papers on focused topics have also garnered a great deal of interest, including the management of MRI waiting lists, reasons why nurses migrate to the US, and mental health indicators. There have also been shifting clusters of papers submitted over time. Access to care and waiting times were a focus in the early years of the journal, followed by a large number of papers on primary healthcare. We continue to publish on both topics, but more recently we have seen an increase in submissions related to pharmaceutical policy and comparative health systems. Both are issues of high policy relevance today and are reflected in the contents of this issue of the journal. It features articles addressing a diverse set of questions relevant to pharmaceutical policy, from direct-to-consumer advertising and health technology assessment to reimbursement for drugs for rare diseases and the impact of private insurance on drug use. One thing that has not changed in the last decade is that producing a high quality jour-
doi:10.12927/hcpol.2015.24207 fatcat:gd2uvosdvnafviqkthyyobnoaq